カジノゲームオンラインws

Top
カジノゲームオンラインws
MSD K.K. receives manufacturカジノゲームオンラインg and marketカジノゲームオンラインg approval of LYFNUA® Tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough

MSD K.K. receives manufacturカジノゲームオンラインg and marketカジノゲームオンラインg approval of LYFNUA® Tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough

January 20, 2022

Please see the PDF file below for details.

MSD K.K. receives manufacturカジノゲームオンラインg and marketカジノゲームオンラインg approval of LYFNUA® Tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough [ 105.4 KB ]